Keywords: Novartis, Bexsero, Meningococcal infections, Vaccine

Novartis says Bexsero shows significant potential against meningococcal serogroup B infections

Article | 10 June 2011

Print This

Swiss drug major Novartis (NVN: VX) says that new data from a pivotal study in more than 1,800 infants show that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in